Compugen (CGEN) Financials: History & Chart

Compugen Ltd.(CGEN)

Biotechnology · Holon, TA

$2.27-0.04 (-1.95%)

Delayed quote: Oct 6, 2026, 10:55 AM EDT

About Compugen Ltd.

Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.

Holon, TA

75 employees

cgen.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Eran Ophir

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	74.00M	2.60M	2.18M	67.33M	1.89M	1.26M	2.28M	1.47M	17.13M
Cost of Goods Sold	9.70M	2.69M	1.82M	3.54M	1.65M	1.67M	2.40M	675K	3.60M
Gross Profit	64.30M	-92K	352K	63.80M	241K	-408K	-116K	796K	13.53M
Gross Profit Margin	86.9%	-3.5%	16.2%	94.7%	12.7%	-32.5%	-5.1%	54.1%	79.0%
Total Operating Expenses	34.00M	8.74M	9.37M	7.75M	8.13M	8.02M	8.28M	8.28M	9.04M
Research & Development	24.59M	6.31M	6.94M	5.54M	5.80M	5.64M	5.77M	5.91M	6.31M
Selling, General & Administrative	9.41M	2.44M	2.43M	2.21M	2.33M	2.38M	2.51M	2.37M	2.73M
Operating Income (EBIT)	30.30M	-8.84M	-9.02M	56.04M	-7.89M	-8.43M	-8.39M	-7.48M	4.50M
Operating Margin	40.9%	-339.6%	-414.4%	83.2%	-417.4%	-670.6%	-367.6%	-508.7%	26.2%
Income Before Tax (EBT)	35.24M	-7.00M	-7.66M	56.84M	-6.94M	-7.36M	-7.15M	-6.11M	5.78M
Interest Income	3.43M	1.84M	N/A	636K	954K	1.07M	1.25M	1.39M	1.28M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	4.95M	1.84M	1.35M	802K	954K	1.07M	1.25M	1.37M	1.28M
Net Income	35.19M	-7.01M	-7.67M	56.84M	-6.98M	-7.34M	-7.18M	-6.12M	1.28M
Income Tax Expense	52K	7K	5K	0.00	40K	-17K	31K	4K	4.50M
Net Profit Margin	47.6%	-269.3%	-352.4%	84.4%	-369.1%	-584.1%	-314.4%	-415.8%	7.4%
EBITDA	30.30M	-8.84M	-9.02M	56.04M	-7.89M	-8.43M	-8.39M	-7.48M	4.50M
EBITDA Margin	40.9%	-339.6%	-414.4%	83.2%	-417.4%	-670.6%	-367.6%	-508.7%	26.2%
Depreciation & Amortization	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS Basic	0.38	-0.07	-0.08	0.60	-0.07	-0.08	-0.08	-0.07	0.01
EPS Diluted	0.38	-0.07	-0.08	0.60	-0.07	-0.08	-0.08	-0.07	0.01
Weighted Average Basic Shares	94.64M	94.64M	94.56M	94.30M	93.54M	93.53M	92.31M	89.54M	89.54M
Weighted Average Diluted Shares	94.64M	94.64M	94.56M	94.71M	93.54M	93.53M	92.31M	89.54M	89.82M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	72.76M	27.86M	33.46M	7.50M	6.00M	2.00M	0.00	17.80M
Cost of Goods Sold	9.25M	7.93M	2.00M	975K	680K	60K	989K	1.03M
Gross Profit	63.51M	19.93M	31.45M	6.53M	5.32M	1.94M	-989K	16.77M
Gross Profit Margin	87.3%	71.5%	94.0%	87.0%	88.7%	97.0%	N/A	94.2%
Total Operating Expenses	32.19M	34.83M	44.45M	41.90M	40.39M	33.44M	28.88M	39.99M
Research & Development	22.76M	24.81M	34.47M	30.65M	28.69M	22.76M	19.82M	30.32M
Selling, General & Administrative	9.43M	10.02M	9.97M	11.25M	11.70M	10.68M	9.06M	9.68M
Operating Income (EBIT)	31.33M	-14.89M	-12.99M	-35.37M	-35.07M	-31.50M	-28.88M	-23.23M
Operating Margin	43.1%	-53.4%	-38.8%	-471.7%	-584.6%	-1574.8%	N/A	-130.5%
Income Before Tax (EBT)	35.40M	-9.71M	-9.78M	-33.64M	-34.20M	-29.70M	-28.06M	-22.60M
Interest Income	4.41M	5.24M	3.24M	1.44M	894K	1.76M	935K	643K
Interest Expense	N/A	34K	31K	27K	25K	42K	32K	620K
Other Income/Expense	4.07M	5.18M	3.21M	1.74M	871K	1.80M	820K	628K
Net Income	35.34M	-14.23M	-18.75M	-33.69M	-34.20M	-29.70M	-27.34M	-22.60M
Income Tax Expense	54K	4.52M	8.97M	58K	0.00	0.00	-722K	0.00
Net Profit Margin	48.6%	-51.1%	-56.1%	-449.3%	-570.0%	-1484.9%	N/A	-127.0%
EBITDA	31.80M	-14.40M	-12.52M	-34.89M	-34.61M	-30.78M	-27.89M	-21.83M
EBITDA Margin	43.7%	-51.7%	-37.4%	-465.2%	-576.9%	-1539.0%	N/A	-122.7%
Depreciation & Amortization	475K	486K	476K	482K	461K	715K	989K	1.39M
EPS Basic	0.38	-0.16	-0.21	-0.39	-0.41	-0.37	-0.43	-0.41
EPS Diluted	0.38	-0.16	-0.21	-0.39	-0.41	-0.37	-0.43	-0.41
Weighted Average Basic Shares	93.43M	89.53M	87.63M	86.56M	84.20M	79.59M	63.64M	55.28M
Weighted Average Diluted Shares	93.82M	89.53M	87.63M	86.56M	84.20M	79.59M	63.64M	55.28M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.